Todd A. Mahr, MD
Director, Pediatric Allergy
Gundersen Lutheran Medical Center
Department of Pediatrics
University of Wisconsin School of Medicine
Gabriel R. Ortiz, MPAS, PA-C
Pediatric Pulmonary Services, El Paso, Texas
Co-founder American Academy of Physician Assistants – Allergy, Asthma, and Immunology, AAPA Liaison to American Academy of Allergy, Asthma and Immunology, American Academy of Allergy, Asthma and Immunology Liaison to AAPA
1.25 hours of AAPA Category I CME
CREDIT FOR THIS ACTIVITY IS AVAILABLE FOR PHYSICIAN ASSISTANTS ONLY.
Originally presented live on Sunday, May 27, 2007 in conjunction with the American Academy of Physician Assistants’ 35th Annual Physician Assistant Conference in Philadelphia, PA.
This Adjunct Symposium was not part of the official CME agenda as planned by AAPA’s Conference Education Program Committee.
Up to 40% of Americans suffer from some form of allergic rhinitis, a syndrome often characterized by a collection of symptoms that include sneezing, nasal congestion, nasal itching, and rhinorrhea. When poorly controlled, the condition is often associated with other comorbidities, such as asthma and sinusitis. Allergic rhinitis and its comorbidities significantly affect the quality of life in those affected by restricting the patient’s daily activities. This results in decreases in performance and productivity while at school or work and increases in absenteeism. Even though people spend billions of dollars annually on physician visits, prescription medications, and over-the-counter medications to remedy their symptoms, only a quarter of those patients feel that their symptoms are well controlled. Additionally, accurate diagnosis of rhinitis directs treatment, so clinicians need to be familiar with the proper classification scheme used in rhinitis syndromes. Using a case-based approach, this activity will help physician assistants to appropriately identify and classify their patients’ rhinitis. Suitable medications and their role in the treatment of allergic rhinitis will also be discussed.
. Target Audience
This program is designed for physician assistants caring for patients with allergic rhinitis.
Upon completion of this educational activity, the participant should be able to:
Discuss the prevalence of allergic rhinitis and nonallergic rhinitis.
Recognize the burden of allergic rhinitis.
Describe the appropriate diagnosis and classification of rhinitis.
Develop an appropriate treatment plan for allergic rhinitis.
Todd A. Mahr, MD discloses that he has received honoraria, consultant fees, and research support, and is a member of speakers’ bureaus for GlaxoSmithKline, Alcon Laboratories, Genentech, Merck, Novartis, Schering-Plough, sanofi-aventis, and Verus Pharmaceuticals.
Gabriel Ortiz, MPAS, PA-C discloses that he is a consultant for Altana Pharma, AstraZeneca, Genentech, sanofi-aventis, and Schering-Plough, and is a member of speakers’ bureaus for Abbott Laboratories, AstraZeneca, Genentech, Novartis, sanofi-aventis, Schering-Plough, and Pfizer. Credit Statements
This program has been reviewed and is approved for a maximum of 1.25 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity.
This program was planned in accordance with AAPA’s CME Standards for Live Programs and for Commercial Support of Live Programs.
Commercial Support Statements
This program is supported by an educational grant from Schering-Plough.
©2007, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and in the symposium are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Physician Assistants, or Schering-Plough. Any medications or other diagnostic or treatment procedures discussed by the program faculty should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.